The results of CD8+T cell immunofluorescence staining showed that the CD8+T cell content in the tumor tissue of osimertinib combined with the bevacizumab group was higher than that of the osimertinib single-agent group (Figures 5(c) and 5(d)). The gene discussed is CD8A; the disease is neoplasm.